Celladon Corporation is an exciting new biotechnology company focused on developing treatments for cardiovascular diseases through the application of scientific discoveries in molecular cardiology.Celladon is dedicated to the commercialization of innovative therapeutics based on the understanding of molecular cardiology. Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new biotechnological tools, have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular therapeutics
| Contact Details: |
| 2223 Avenida de la Playa #206 |
| La Jolla |
| California |
| 92037 |
| United States of America |
| Tel: | 858.366.4288 |
| Fax: | 858.964.0974 |
| Email: | info@celladon.net |
| WWW: | www.celladon.net/
|
|
Loading...
|
Press Releases on Celladon Corporation:
|
 |
| Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting |
28th May, 2009 |
Celladon Corporation |
Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients;
Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers
SAN DIEGO, May 28 /PRNewswire/ --
|
| Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy |
26th May, 2009 |
Celladon Corporation |
Phase 1/2 Calcium Upregulation by Percutaneous Administration (CUPID) Data Highlight Safety Profile and Biological Effects of SERCA2a Enzyme Replacement
SAN DIEGO, May 26 /PRNewswire/ -- Celladon
|
| The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure |
8th April, 2009 |
Celladon Corporation |
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated Safety and Biological Effects of SERCA2a Enzyme Replacement Using Gene Transfer
SAN
|
| Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions |
9th November, 2008 |
Celladon Corporation |
NEW ORLEANS, Nov. 9 /PRNewswire/ -- Celladon Corporation announced
today results from the first nine patients treated with MYDICAR(R), a
genetically-targeted enzyme replacement therapy for
|
| WeissComm Partners Announces Several New Hires to Provide Topnotch Service for Expanding Business |
4th September, 2008 |
WeissComm Partners, Inc. |
NEW YORK and SAN FRANCISCO, Sept. 4 /PRNewswire/ -- WeissComm Partners,
the largest independent communications agency focused exclusively on the
healthcare industry, today announced several key
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 430 times since April 2007, the link to the organisation's website has been followed 49 times
Recent Search Terms used to find this page: celladon | celladon | emails Celladon Corporation | celladon therapeutics corp | celladon cupid | celladon corporation financials | .
Search for more companies in La Jolla
Search for more companies in California
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Celladon Corporation
